Pharmacokinetics of two components in felodipine-enalapril sustained-release tablets in Chinese healthy volunteers

doi:10.5246/jcps.2015.07.055

Abstract

Abstract:

To compare the pharmacokinetics properties of enalapril-felodipine sustained-release tablet with enalapril and felodipine in the two reference formulations in Chinese healthy volunteers,the study was designed to a randomized, open label, crossover and two treatment pharmacokinetic study using enalapril-felodipine sustatined-release tablet as the test formulation. A total of 12 individuals were randomly assigned to 2 gorups (6 individuals in each group). The wash-out period was 14 d. Compared with the reference formulations, felodipine in the sustained-release tablet showed significantly sustained-release characteristics, while the pharmacokinetics processes of enalapril and its active metabolite enalaprilat were basically similar in Chinese healthy volunteers.

Key words: Felodipine, Enalapril, Enalaprilat, Pharmacokinetics

CLC Number:

R969.1

Supporting:

Cite this article

Yisha Lv, Liling Ran, Wei Wu, Sanwang Li, Rui Zhou, Fang Tang, Peng Yu, Lingli Mu, Zeneng Cheng. Pharmacokinetics of two components in felodipine-enalapril sustained-release tablets in Chinese healthy volunteers[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(7): 427-432.

share this article

0
/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: http://jcps.bjmu.edu.cn/EN/10.5246/jcps.2015.07.055

http://jcps.bjmu.edu.cn/EN/Y2015/V24/I7/427

References

[1] Arafat, T.; Awad, R.; Hamad, M.; Azzam, R.; AI-Nasan, A.; Jehanli, A. J. Clin. Pharm. Ther. 2005, 30, 319-328.

[2] Miglioranca, L.H.; Barrientos-Astigarraga, R.E.; Schug, B.S.; Schug, B.S.; Blume, H.H.; Pereira, A.S. J. Chromatogr. B. 2005, 814, 217-223.

[3] Gu, Q.; Chen, X.; Zhong, D.; Wang, Y. J. Chromatogr. B. 2004, 813, 337-342.

[4] Portoles, A.; terleira, A.; Almeida, S.; Garcia-Arenillas, M.; Caturla, M.; Filipe, A. Curr. Therap. Res. 2004, 65, 34-46.

[5] MacFadyen, R.J.; Meredith, P.A.; Elliott, H.L. Clin. Pharmaco-kinet. 1993, 25, 274-282.

[6] Little, W.C.; Cheng, C.P.; Elvelin, L.; Nordlander, M. Cardiovasc. Drug Ther. 1995, 9, 657-663.

[7] Todd, P.A.; Faulds, D. Drugs.1992, 44, 251-277.

[8] Elvelin, L.; Jonsson, L. Curr. Ther. Res. 1994, 55, 736-746.

[9] Pannarale, G.; Puddu, P.E.; Monti, F.; Irace, L.; Bentivoglio, M.; Collauto, F.; Barsotti, A.; Corea, L.; Trevi, G.; Campa, P.P.; Jacono, A. J. Cardiovasc. Pharmacol. 1996, 27, 255-261.

[10] Saltiel, E.; Ellrodt, A.G.; Monk, J.P.; Langley, M.S. Felodipine. Drugs. 1998, 36, 387-428.

[11] Azie, N.E.; Brater, D.C.; Becker, P.A.; Jones, D.R.; Hall, S.D. Clin. Pharmacol. Ther. 1998, 64, 369-377.

[12] Shammas, F.V.; Dickstein, K. Clin. Pharmacokinet. 1998, 15, 94-113.

[13] Morgan, T.O.; Anderson, A.; Jones, E. Am. J. hyperten. 1992, 5, 238-243.

[14] Epstein, M.; Bakris, G. Arch. Intenr. Med. 1996, 156, 1969-1978.

[15] Sica, D.A. Drugs. 1994, 48, 16-24.

[16] Gradman, A.H.; Cutler, N.R.; Davis, P.J.; Robbins, J.A.; Weiss, R.J.; Wood, B.C. Am. J. Cardiol. 1997, 79, 431-435.

[17] Applegate, W.B.; Cohen, J.D.; Wolfson, P.; Davis, A.; Green, S. Am. J. Cardiol. 1996, 78, 51-55.

[18] Frishman, W.H.; Ram, C.V.S.; McMahon, F.G. J. Clin. Pharmacol. 1995, 35, 1060-1066.

Related Articles 15

[1]	Yanfang Yang, Wei Wei, Lei Zhang, Wei Xu, Xiuwei Yang. Simultaneous quantification of 37 constituents in Duliang Pill by UPLC-MS/MS: Application to the pharmacokinetic studies in rat plasma [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 560-573.
[2]	Yingyuan Lu, Mei Zhang, Shengju Yin, Xiaona Dong, Zhiyuan Zhang, Haixu Cheng, Pengfei Tu, Guifang Dou, Yongsheng Che, Zhenghui Xu, Feng Xu, Xian Wang, Chuang Lu, Yaqing Lou, Guoliang Zhang. Epigenetic variants of xenobiotic metabolism affect individual differences in antiepileptic drug 3,4-DCPB pharmacokinetic phenotype [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(1): 1-16.
[3]	Min Li, Lulu Chang, Xiangfeng Yue, Shuzhang Du. Efficacy and safety of ACEI plus tanshinone for acute exacerbation of pulmonary heart disease: a meta-analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(11): 853-865.
[4]	Yanan Li, Xue Guo, Ye Yuan, Weichong Dong, Xiuling Yang. Determination of free ceftriaxone concentration and its application in predicting lung tissue concentration [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(7): 578-589.
[5]	Xiaojiao Li, Shuxin Luan, Hong Zhang, Hongquan Wan, Hong Chen, Chengjiao Liu, Chang Liu, Yanhua Ding. Pharmacokinetics, pharmacodynamics and safety of a single-dose long-acting Risperidone injection in Chinese patients with schizophrenia [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(3): 206-217.
[6]	Yan Zhou, Hengwen Song, Zhichao Shao, Bomin Yin, Ximei Fu, Dianyou Xie, Lijun Wei. Preclinical efficacy of a novel cyclin-dependent kinase 9 inhibitor, QHRD107 against acute myeloid leukemia [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(2): 146-156.
[7]	Ye Yuan, Bo Yu, Xueqin Zhang, Yanan Li, Shumei Wang. Effects of Zhenyuan capsule on the pharmacokinetics comparison of simvastatin and its active metabolites in rats [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(7): 494-503.
[8]	Jin Zhang, Weiwei Lin, Wei Wu, Xianzhong Guo, Pinfang Huang, Xinhua Lin, Zheng Jiao, Changlian Wang. Population pharmacokinetics of vancomycin in Chinese elderly patients and its application for dose individualisation [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(4): 260-271.
[9]	Xinyu Chang, Tao Guo, Guiming Guo . Effect of CYP3A4 genetic polymorphisms on pharmacokinetics of tinidazole [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(4): 272-279.
[10]	Shengxin Wang, Xiangli Yan, Haozhen Zheng, Jianye Yu, Aiming Yu, Xiao Shen, Lisheng Wang. Pharmacokinetics of different dosage of astragalus membranaceus of buyang huanwu decoction in rats with cerebral ischemic injury by microdialysis combined with LC/MS [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(2): 90-101.
[11]	Jingjing Cao, Jun Sun, Shujuan Zhao, Peizhi Ma. Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 729-733.
[12]	Xin Liu, Bo Zhang, Dan Mei, Kai Huang. Rapid and sensitive HPLC-MS/MS method for quantitative determination of isochlorogenic acid B in rat plasma and its application in pharmacokinetic study [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 167-173.
[13]	Xiwei Ji, Zisheng Kang, Yun Li, Xiping Yang, Xifeng Ma, Chongtie Shi, Yuan Lv. An established LC-MS/MS method and a developed PK model for the study of pharmacokinetic properties of benapenem in infected mice [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(11): 802-811.
[14]	Lingling Zhang, Huiwen Zhang, Shikui Wu, Hong Liu, Jingyuan Li, Xin Dong, Huimin Xia, Huanyun Wang. Simultaneous determination of the pharmacokinetics of the active components of San-Chen-pill by UPLC-Q-Exactive-MS [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(11): 812-824.
[15]	Wenjuan OuYang, Yalan Zhang, Pingsheng Xu, Zhiyong Dai, Hongying Ma, Qun Qin. Pharmacokinetics of Pazufloxacin Mesilate Sodium Chloride in healthy Chinese volunteers after intravenous injection [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(1): 40-48.

Metrics

Viewed

Full text

Abstract

Comments

Abstract
References
Related Articles
Recommended Articles
Metrics
Comments

TOP